Latest Information Update: 28 Jul 2004
At a glance
- Originator Xenova Group
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 27 Jul 2004 Discontinued - Preclinical for Ulcerative colitis in United Kingdom (unspecified route)
- 11 Nov 2003 Preclinical trials in Ulcerative colitis in United Kingdom (unspecified route)